The Alexion Pharmaceuticals stock price gained 0.0924% on the last trading day (Friday, 12th Mar 2021), rising from $151.45 to $151.59. Find out now with a free analysis on Alexion Pharmaceuticals. Alexion Pharmaceuticals Stock: Machine Learning Powered Price Prediction (ALXN) | Transparent & Simple Alexion Pharmaceuticals Stock Prediction & Volatility Models Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. In the past three months, Alexion Pharmaceuticals insiders have not sold or bought any company stock. Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Alexion Stock Analysis: New Management Will Lead ALXN in a Prosperous Direction - Stock Forecast Based On a Predictive Algorithm | I Know First | . High institutional ownership can be a signal of strong market trust in this company. All rights reserved. Jeff Brown, member of a D.C.-based advocacy group, explains what every American must do before May 28th to preserve his assets and thrive. Alexion Pharmaceuticals Stock Forecast NASDAQ:ALXN Price Target and Analyst Ratings. Should I buy or sell ALXN? Alexion Pharmaceuticals updated its FY 2020 Of those polled by FactSet, 84% rate it at Buy or Overweight. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Alexion Pharmaceuticals Inc has risen higher in 15 of those 24 years over the subsequent 52 week period, corresponding to a historical accuracy of 62.5 % Learn about financial terms, types of investments, trading strategies and more. Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology, AstraZeneca Sold Its Stake in Rival Covid-19 Vaccine Maker Moderna for More Than $1 Billion, AstraZeneca sold its stake in Moderna for more than $1 billion last year. Get daily stock ideas top-performing Wall Street analysts. Alexion also produces Strensiq, which treats a rare disorder known as hypophosphatasia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. On average, they anticipate Alexion Pharmaceuticals' share price to reach $155.68 in the next twelve months. With an impressive revenue growth forecast and healthy cash flows, Alexion is a growth stock which is currently priced as a value play. With a market capitalization of $33,435,734,724, Alexion Pharmaceuticals Inc has a greater market value than 92.44% of US stocks. Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. The business's revenue was up 15.0% compared to the same quarter last year. Alexion Pharmaceuticals employs 3,082 workers across the globe. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. CNN Sans™ & © 2016 Cable News Network. Shares of ALXN can be purchased through any online brokerage account. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Shares have climbed 7% year to date through Monday. View all of ALXN's competitors. Alexion Pharmaceuticals has received a consensus rating of Hold. Since then, ALXN shares have increased by 80.2% and is now trading at $150.94. View Alexion Pharmaceuticals' earnings history. There are currently 16 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Their forecasts range from $73.00 to $196.00. Good spot for Alexion Pharmaceuticals. Shares in Alexion Pharmaceuticals Inc are currently priced at $151.56. ALXN Stock Analysis - [Full Report] Free Signup: Advanced stock screener. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 ), Alexion Pharmaceuticals has received 770 “underperform” votes. Shares of Alexion are down 11% over the past 12 months, though the stock is beloved by sell-side analysts. The stock has a consensus analyst rating of "Hold." You Must Recognize Your Own Achievements First Before Expecting … The stock is down by more than 5% after the company revealed that it would acquire Alexion in a $39 billion deal. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Wednesday, February, 3rd. Company Forecast. The company's average rating score is 2.35, and is based on 6 buy ratings, 16 hold ratings, and no sell ratings. 87.27% of the stock of Alexion Pharmaceuticals is held by institutions. Who this matters to: Overall Ranking is a comprehensive evaluation. Learn everything you need to know about successful options trading with this three-part video course. If they elect, Alexion shareholders may receive their allocation of AstraZeneca ADSs in the form of a corresponding number … 4:35p Tesla Inc. stock rises Thursday, outperforms market 4:33p Credit Suisse’s Golub ups S&P 500 forecast to 4,200: ‘There is no risk on valuations’ View Alexion Pharmaceuticals' (NASDAQ:ALXN) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. This represents a 45% premium on Alexion's current stock price. © 2020 Cable News Network. Mar 18 / GuruFocus News - Paid Partner Content, Mar 09 / Zacks.com - Paid Partner Content, Mar 13 / MotleyFool.com - Paid Partner Content, Mar 06 / Zacks.com - Paid Partner Content, Analysts: Focus on AstraZeneca's Positives, Not Vaccine Issue, Immunovant (IMVT) Gains on a Potential Buyout by Roivant. Historical Ratings. Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V). You can opt out at any time. View the latest Alexion Pharmaceuticals Inc. (ALXN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Company Releases for Alexion Pharmaceuticals Inc. Tuesday, March 16, 2021. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Alexion and Caelum Biosciences are conducting the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101, a first-in-class amyloid fibril targeted therapy, in combination with standard-of-care therapy in AL amyloidosis. Get the latest Alexion Pharmaceuticals (ALXN) stock price quote with real-time news, financials, charts and other important investing information. Brian, what do you think of this deal and how does it fit into AstraZeneca's strategy? Other top laggards in the FTSE are Fresnillo, PolyMetal, and BHP. During the same period last year, the company earned $2.71 EPS. Was AstraZeneca Smart to Sell Its Moderna Shares? View real-time stock prices and stock quotes for a full financial overview. Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria - two … Alexion Pharmaceuticals has a PEG Ratio of 0.75. Alexion Pharmaceuticals has received 61.88% “outperform” votes from our community. An Overall Rank of 82 means that our comprehensive methodology rates Alexion Pharm Inc above 82% of stocks. Since then, ALXN stock has increased by 81.0% and is now trading at $151.59. Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. At that level they are trading at 13.89% discount to the analyst consensus target price of 0.00. Last 30 Days. The price target was set to $175.00. Non-stationary data are called the data whose statistical properties e.g. VP and Chief Commercial & Global Operations Officer. The company was founded in 1992 and is headquartered in Boston, Massachusetts. Institutions hold 93.36% of the Float. As of February 12th, there was short interest totaling 7,900,000 shares, an increase of 80.4% from the January 28th total of 4,380,000 shares. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). The biopharmaceutical company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.51 billion. "ALXN" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. PEG Ratios below 1 indicate that a company could be undervalued. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, and Tanisha Carino. Alexion Pharmaceuticals saw a increase in short interest in the month of February. Alexion Pharmaceuticals Stock Forecast is based on your current time horizon. Alexion Pharmaceuticals was founded in 1992. View which stocks … Scan for strong stocks. Learn more about I Know First. Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN.". As of 2021 March 17, Wednesday current price of ALXN stock is 150.100$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Alexion Pharmaceuticals stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. All rights reserved. MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Never miss a profitable trade. This suggests the company knows how to effectively market the drugs it develops, but it still has the Achillion acquisition to incorporate. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]. Alexion Pharmaceuticals has a market capitalization of $33.18 billion and generates $4.99 billion in revenue each year. Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter. About the Alexion Pharmaceuticals, Inc. stock forecast. So far, Alexion is up 12 percent in 2020. However, solely looking at the historical price movement is usually misleading. Vote “Outperform” if you believe ALXN will outperform the S&P 500 over the long term. What this means: Alexion Pharm Inc (ALXN) gets a very positive evaluation from InvestorsObserver's ranking system. The P/E ratio of Alexion Pharmaceuticals is 35.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 32.54. A Warner Media Company. The combination is tenuous, but not impossible. ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth, AstraZeneca Sees Profit Accelerating After Turnaround Effort, Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation, Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates, Alexion Reports Fourth Quarter and Full Year 2020 Results, Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Surpass Estimates, Zacks.com featured highlights include: Vale, Canadian Solar, Alexion Pharmaceuticals and Affiliated Managers Group. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. View which stocks have been most impacted by COVID-19. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Factset: FactSet Research Systems Inc.2019. A "hold" rating indicates that analysts believe investors should keep any existing positions they … Alexion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Most Recent Rating. Their average twelve-month price target is $155.68, predicting that the stock … Alexion Pharmaceuticals Inc (ALXN:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Negative news sentiment. I was waiting for today's opening to confirm a bullish position. What this means: Alexion Pharm Inc (ALXN) gets a very positive evaluation from InvestorsObserver's ranking system. The combination is tenuous, but not impossible. Vote “Underperform” if you believe ALXN will underperform the S&P 500 over the long term. Find the latest Earnings Report Date for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ALXN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, First Trust Advisors LP, AJO LP, Iridian Asset Management LLC CT, Renaissance Technologies LLC, and Clearbridge Investments LLC. According to our live Forecast System, Alexion Pharmaceuticals Inc. stock is a bad long-term (1-year) investment*. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The stock was up 2.39% to $118.00 in premarket trading. Sadly Bell’s April 2015 retirement left Alexion in poor hands. Currency USD. AstraZeneca stock has the potential to push above $61 per share, aided in part by the drug maker's pending buyout of Alexion, says Jefferies. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Alexion Pharmaceuticals does not currently pay a dividend. Editor of top German newspaper suspended in compliance probe. Ludwig Hantson has an approval rating of 75% among Alexion Pharmaceuticals' employees. All rights reserved. Alexion Pharmaceuticals stock forecast & analyst price target predictions based on 8 analysts offering 12-months price targets for ALXN in the last 3 months. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? Investors can use this forecasting interface to forecast Alexion Pharmaceuticals historical stock prices and determine the direction of Alexion Pharmaceuticals's future trends based on various well-known forecasting models. Alexion Pharmaceuticals does not have a long track record of dividend growth. AC Investment Inc. delivers machine learning based share price forecast. The biopharmaceutical company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.56 by $0.40. Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021. During the day the stock fluctuated 1.28% from a day low at $149.87 to a day high of $151.78. Alexion enjoyed 44% annual revenue growth between 1996 and 2015 — driving its stock to a peak of $204 in July 2015. Alexion Pharmaceuticals Stock Forecast is based on your current time horizon. How Many Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Do Institutions Own? The P/E ratio of Alexion Pharmaceuticals is 35.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 40.72. ALXN stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Magnetar Financial LLC, Janus Henderson Group PLC, The Manufacturers Life Insurance Company, Westchester Capital Management LLC, Alpine Associates Management Inc., Carlson Capital L P, and Water Island Capital LLC. Alexion closed at $120.97 Wednesday, a 3.4% decrease from the same date three years ago. DOW 32,778.64. According to present data Alexion Pharmaceuticals's AXP shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). The official website for Alexion Pharmaceuticals is www.alexion.com. Do Not Sell My Information. Identify stocks that meet your criteria using seven unique stock screeners. ALXN Stock Summary. Source: Schwab Stocks Research. Alexion Pharmaceuticals had a net margin of 16.32% and a trailing twelve-month return on equity of 23.16%. The stock is trading above the Ichimoku Cloud Support (red line of the green cloud). Want to see which stocks are moving? MarketBeat just released five new trading ideas, but Alexion Pharmaceuticals wasn't one of them. View real-time stock prices and stock quotes for a full financial overview. After all, Alexion [NASDAQ: ALXN] has been around for more than two decades and it has successfully brought several products to market. 09:24 AM ET. Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Pre-Market earnings guidance on Tuesday, January, 12th. View which stocks are hot on social media with MarketBeat's trending stocks report. 43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com. The price target was set to $175.00. Time-series forecasting models ae widely used for non-stationary data. © American Consumer News, LLC dba MarketBeat® 2010-2021. View analysts' price targets for Alexion Pharmaceuticals or view top-rated stocks among Wall Street analysts. After all, Alexion [NASDAQ: ALXN] has been around for more than two decades and it has successfully brought several products to market. Alexion Pharmaceuticals, Inc. Common Stock (ALXN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Learn more. Hypophosphatasia prevents the body from processing calcium and phosphorus, affecting approximately 1 in 100,000 individuals. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. Alexion Pharmaceuticals Stock Forecast Summary. 23 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. Why is AstraZeneca share price falling? It considers technical and fundamental factors and is a good starting point for evaluating a stock. (Add your “outperform” vote. Find real-time ALXN - Alexion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. View insider buying and selling activity for Alexion Pharmaceuticals or view top insider-selling stocks. Alexion Pharmaceuticals stock price forecast for further price development up to 2.20% (time horizon: 1 day) and price target of 156.12 USD. Even after Ultomiris’ launch in late 2018, the company’s stock price has stayed pretty much flat. Even after Ultomiris’ launch in late 2018, the company’s stock price has stayed pretty much flat. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares. 09:11 PM ET
Heilige Der Katholischen Kirche Kreuzworträtsel,
Unfall Kassel Frankfurter Straße Heute,
Goon 2 Film,
Como Se Chama A Organização Criada Por Wangari Maathai,
Motherland: Fort Salem Episodenguide,
Sioux Schuhe Mainz,